Pfizer to pay $24mn as settlement amount in copay assistance lawsuit
Date: 2018-05-29   Author: Saipriya Iyer  Category: #market

Pfizer to pay $24mn as settlement amount in copay assistance lawsuit

Pfizer Inc., a U.S. based pharma firm, has decided to pay about USD 24 million as a part of the settlement deal to resolve charges against the firm over directing Medicare patients towards a Pfizer financed Patient Access Network (PAN) foundation. Reportedly, during the 2012-2016 span, Pfizer had provided PAN, a copay assistance non-profit institution, with donations. The pharma giant then hired the services of a Speciality Pharma firm for encouraging its Medicare patients towards PAN for copay coverage.

Attorney Andrew Lelling, a U.S. Prosecutor, has claimed that the Pharma giant was well-aware that the third-party institution was making use of its funds to cover the copays of patients consuming Pfizer medicines. He further asserted that the move produced more income for Pfizer in addition to hiding the impact of increasing the cost of its drugs.

Reportedly, the Anti-Kickback Statute offers protection to Medicare coverage as well as taxpayers in the U.S. who invest in it. Experts are of the view that Pfizer violated the U.S. federal laws as pharmaceutical firms across the country cannot offer copay assistance to the beneficiaries of either Medicaid or Medicare.

The Pfizer manufactured drug at the center of the dispute was Sutent, which caused a loss of USD 47,000 to Medicare per patient. Sources cite that the expenditure of Medicare on each drug unit had increased up to 80% during 2012-2016 period. Inlyta reportedly caused a loss of nearly USD 73 million to Medicare in 2016 and the latter invested 34% more on each drug unit in 2016 as compared to its investment during 2012.

Tikosyn, another medicine manufactured by Pfizer, was also a part of the allegation during the settlement issue. Statistics reveal that Pfizer had increased the costs of the 40 drug capsules from USD 220 to USD 317 during the last quarter of 2015 and it caused a loss of nearly USD 107 million to Medicare in the pre-rebate period.



About Author


Saipriya Iyer

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

More from Saipriya


Post Recommendents

Worldwide N-Methylethanolamine Market Forecast 2021-2026 Growth Drivers, Regional Outlook
Author: Ashwin Naphade

Market Study Report, LLC, has added an exhaustive research study of the ' N-Methylethanolamine market', detailing every single market driver and intricately analyzing the business vertical. This ' N-Methylethanolamine market' study...


2026 Projections: Transient Voltage Suppressor Diodes Market Report by Type, Application and Regional Outlook
Author: Ashwin Naphade

The ' Transient Voltage Suppressor Diodes market' report added recently by Market Study Report, LLC, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a prec...


Worldwide Oxygen Regulator Market Study for 2021 to 2026 providing information on Key Players, Growth Drivers and Industry challenges
Author: Ashwin Naphade

The ' Oxygen Regulator market' report Added by Market Study Report, LLC, enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive i...